Early Transcatheter Mitral Valve Repair After Myocardial Infarction

Launched by FUNDACIÓN PARA LA INVESTIGACIÓN BIOSANITARIA DEL PRINCIPADO DE ASTURIAS · Feb 27, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment for people who have severe mitral regurgitation (a condition where the heart's mitral valve doesn’t close properly, causing blood to flow backward) after a heart attack. The researchers want to see if early intervention using a procedure called transcatheter edge-to-edge repair can help improve outcomes for patients. They will check if this treatment reduces the chances of death and hospital visits due to heart failure in the first year, as well as assess quality of life and heart function changes over two years.

To be eligible for this trial, participants must be adults over 18 years old who are experiencing symptoms from moderate to severe mitral regurgitation following a heart attack. However, those with certain conditions, such as severe heart dysfunction or who are going to have bypass surgery, won't be able to join. If someone participates, they can expect close monitoring and follow-up to track their health and heart performance over time. This trial is not yet recruiting participants, but it aims to gather valuable information that could help improve treatment for future patients with similar heart issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with symptomatic moderate to severe or severe MR after acute MI
• • Age \> 18 years
• * Based on the following classification recently published in "Transcatheter Mitral Edge-to-Edge Repair for Treatment of Acute Mitral Regurgitation" by M. Shuvy et al. (Can J Cardiol. 2023) patients will be included if categorized in Type 2, 3 or 4:
• Exclusion Criteria:
• • Primary MR (e.g. papillary muscle rupture)
• • EF ≤ 25%
• • Accepted for CABG
• • Presence of cardiogenic shock (AMR type 1)